Abstract：
KEYNOTE-9421 is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.
摘要：
KEYNOTE-9421是一项针对切除的III期黑色素瘤患者的随机II期佐剂研究，研究了个性化的新抗原mRNA疫苗与抗PD-1的组合。该研究清楚地表明，疫苗加抗PD-1在无复发和无远处转移的生存率方面具有优势，但目前尚无定论，重要的问题依然存在。
